Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes

Inclusion Criteria

• •Patient aged between 40 and 80 years old,
• •Patient with hepatic steatosis determined by conventional abdominal ultrasound as defined by the EASL/EASO/EASD European guidelines.
• •Patient who agrees to be included in the study and who signs the informed consent form,
• •Patient affiliated to a healthcare insurance plan.
• •Evidence of other causes of chronic liver disease :
• •1. Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).
• •2. Previous or current infection with Hepatitis C as defined by presence of hepatitis C virus Ab in serum (anti-HCV Ab).
• •3. Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy.
• •4. Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis.
• •5. Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease.
• •6. Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency.
• •7. Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y/H63D.
• •8. Drug-induced liver disease as defined on the basis of typical exposure and history.
• •9. Bile duct obstruction as shown by imaging studies.
• •History of ingestion of medications known to produce steatosis in the previous 6 months.
• •Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices
• •Presence of regular and/or excessive use of alcohol (defined as \>30g/day for males and \>15g/day for females) for a period longer than 2 years at any times in the last 10 years
• •The subject is a pregnant or nursing female
• •Life expectancy less than 5 years
• •History of known HIV infection
• •History of type 1 diabetes
• •BMI ≥ 45 kg/m2
• •Mentally unbalanced patients, under supervision or guardianship,
• •Patient deprived of liberty,
• •Patient who does not understand French/ is unable to give consent,
• •Patient already included in a trial who may interfere with the study or in a period of exclusion following participation in a previous study.